Analysis of AM-2201 and metabolites in a drugs and driving case

Drug Testing and Analysis

Volumn 6, Issue 4, 2014, Pages 389-395

  Elian, Albert A ^a   Hackett, Jeffery ^b  

^a Massachusetts State Police Crime Laboratory ^*  (United States)

^b UCT Inc   (United States)

Author keywords

AM 2201; Driving; Drugs; Forensic; SPE

Indexed keywords

BIOMOLECULES; BODY FLUIDS; FORENSIC SCIENCE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHANOL; ORGANIC SOLVENTS; PHASE SEPARATION; PROJECTILES;

AM-2201; CASE REPORTS; DRIVING; DRUG; DRUGS AND DRIVING; FORENSIC; HUMAN URINE; PHOSPHATE BUFFERS; PLANT MATERIAL; SPE;

METABOLITES;

1 (5 FLUOROPENTYL) 3 (1 NAPHTHOYL)INDOLE; 1 (5 FLUOROPENTYL) 3 (1 NAPHTHOYL)INDOLE (2 HYDROXYINDOLE); 1 (5 FLUOROPENTYL) 3 (1 NAPHTHOYL)INDOLE N (4 HYDROXYPENTYL); 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; ACETIC ACID ETHYL ESTER; BETA GLUCURONIDASE; CANNABINOID; DELTA 9 TETRAHYDROCANNABINOL CARBOXYLIC ACID; DRUG METABOLITE; METHANOL; UNCLASSIFIED DRUG; 1-(5-FLUOROPENTYL)-3-(1-NAPHTHOYL)INDOLE; INDOLE DERIVATIVE; STREET DRUG;

ARTICLE; CAR DRIVING; DILUTION; DRIVER; EVAPORATION; HUMAN; HYDROLYSIS; MOTOR VEHICLE; PH; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; UNITED STATES; URINALYSIS; CHEMISTRY; ISOLATION AND PURIFICATION; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; METABOLISM; PLANT; PROCEDURES; REPRODUCIBILITY; URINE; VALIDATION STUDY;

AUTOMOBILE DRIVING; CHROMATOGRAPHY, LIQUID; HUMANS; INDOLES; LIMIT OF DETECTION; PLANTS; REPRODUCIBILITY OF RESULTS; SOLID PHASE EXTRACTION; STREET DRUGS; TANDEM MASS SPECTROMETRY;

EID: 84898470100     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1535     Document Type: Article

References (27)

1. A. Makriyannis, H. Deng Preparation of cannabimimetic indole derivatives with cannabinoid CB1 or CB2 receptor binding affinity. PCT Int. Appl. W02001028557 A1 20010426, 2001.
2. Synthetic Drug Act 2011. Available at: www.govtrack.us/congress/bills/112/hr1254/text [15 May 2013].
3. T. Sobelevsky, I. Prasolov, G. Rodchenkov Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test. Anal. 2012, 4, 745.
4. M. Jang, W. Yang, H. Choi, H. Chang, S. Lee, E. Kim, H. Chung Monitoring of urinary metabolites of JWH-018 and JWH-073 in legal cases. Forensic Sci. Int. 2013, 213, 13.
5. A. Wohlfarth, K.B. Scheidweiler, X. Chen, H-F. Liu, M.A. Huestis Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal. Chem. 2013, 85, 3730.
6. A.D. de Jager, J.V. Warner, M. Henman, W. Ferguson, A. Hall LC-MS/MS method for the quantitation of metabolites of eight commonly-used synthetic cannabinoids in human urine - An Australian perspective. J. Chromatogr. B 2012, 897, 22.
7. S. Kneisel, V. Auwärter Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J. Mass Spectrom. 2012, 47, 825.
8. F. Musshoff, B. Medea, G. Kernbach-Wighton, W. Bicker, S. Kneisel, M. Hutter, V. Auwärter Driving under the influence of synthetic cannabinoids ('Spice'): A case series. Int. J. Legal Med. DOI: 10.1007/s00414-013-0864-1z
9. A. Arntson, B. Ofsa, D. Lancaster, J.R. Simon, M. McMullin, B. Logan Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. J. Anal. Toxicol. 2013, 37, 284.
10. A. Derungs, A.E. Schwaninger, G. Mansella, R. Bingisser, T. Kraemer, M.E. Liechti Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol. 2013, 37, 164.
11. R. Denooz, J.C. Vanheugan M. Frederich, P. de Tullio, C. Charlier Identification and structural elucidation of four cannabimimetic compounds (RCS-4, AM-2201, JWH-203 and JWH-210) in seized products. J. Anal. Toxicol. 2013, 37, 56.
12. K. Simolka, R. Lindigkeit, H.M. Schiebel, U. Papke, L. Ernst, T. Beuerle Analysis of synthetic cannabinoids in "spice-like" herbal highs: Snapshot of the German market in summer 2011. Anal. Bioanal. Chem. 2012, 404, 157.
13. H. Choi, S. Heo, S. Sanggil, W. Yang, Y. Park, E. Kim, H. Chung, J. Lee Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. Anal. Bioanal. Chem. 2013, 405, 3937.
14. M. Gustavo, Z. Aturko, G. D'Orazio, R. Gottardo, T. Macchia, F. Tagliaro, S. Fanali Analysis of synthetic cannabinoids in herbal blends by means of nano-liquid chromatography. J. Pharmaceut. Biomed. 2012, 71, 45.
15. R. Gottardo, A. Bertaso, J. Pascali, D. Sorio, G. Musile, E. Trapani, C. Seri, G. Serpelloni, F. Tiagliaro Micellar electrokinetic chromatography: A new simple tool for the analysis of synthetic cannabinoids in herbal blends and for the rapid estimation of their log P values. J.Chromatogr. A 2012, 26, 2335.
16. T. Laussmann, S. Meier-Giebing Forensic analysis of hallucinogenic mushrooms and khat (Catha edulis Forsk) using cation-exchange liquid chromatography. Forensic Sci. Int. 2010, 195, 160.
17. B.K. Matuszewski, M.L. Constanzer, C.M. Chavez-Eng Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75, 3019.
18. K.M. Donohue, R.R. Steiner JWH-018 and JWH-022 as combustion products of AM220. Microgram 2012, 9, 52.
19. D. McQuade, S. Hudson, P.I. Dargan, D.M. Wood First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur. J. Clin. Pharmacol. 2013, 69, 373.
20. J.R. Simmons, C.G. Skinner, J.S. Williams, C.S. Kang, M.D. Schwartz, B.K. Wills Intoxication from smoking 'spice'. Ann. Emerg. Med. 2011, 57, 187.
21. D. Vearrier, K.C. Osterhoudt A teenager with agitation. Pediatr. Emerg. Care 2010, 26, 462.
22. J.C. Canning, A.M. Ruha, R. Pierce, M. Torrey, S.J. Reinhart Severe GI distress after smoking JWH-018. Clin. Toxicol. 2010, 48, 618.
23. J. Lapoint, L.P. James, C.L. Moran, L.S. Nelson, R.S. Hoffman, J.H. Moran Severe toxicity following synthetic cannabinoid ingestion. Clin. Toxicol. (Phila.) 2011, 49, 760.
24. A.L. Patton, K.C. Chimalakonda, C.L. Moran, K.R. McCain, A. Radominska-Pandya, L.P. James, C. Kokes, J. H. Moran K2 toxicity: Fatal case of psychiatric complications following AM2201 exposure. J.Forensic Sci. 2013. DOI: 10.1111/1556-4029.12216
25. M. Hutter, B. Moosmann, S. Kneisel, V. Auwarter Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J. Mass Spctrom. 2013, 48, 885.
26. K.C. Chimalakonda, K.A. Seely, S.B. Bratton, L.K. Brents, C.L. Moran, G.W. Endres, L.P. James, P.F. Hollenberg, P.L. Prather, A. Radominska-Pandya, J. H. Moran Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/spice: Identification of novel cannabinoid receptor ligands. Drug Metab. Dispos. 2012, 40, 2174.
27. M. Jang, W. Yang, I. Shin, H. Choi, H. Chang, E. Kim Determination of AM-2201 metabolites in urine and comparison with JWH-018 abuse. Int. J. Leg. Med. 2013. DOI: 10.1007/s00414-013-0884-x